Francesca E Cunningham1, Kwan Hur1, Diane Dong1, Donald R Miller2,3, Rongping Zhang1, Xiangming Wei1, Madeline McCarren1, Andrew D Mosholder4, David J Graham4, Sherrie L Aspinall1,5,6, Chester B Good1,5,7,6. 1. VA Center for Medication Safety, Hines, IL, USA. 2. Boston University School of Public Health, Boston, MA, USA. 3. Center for Health Quality Outcomes and Economic Research, Bedford, MA, USA. 4. US Food and Drug Administration, Silver Spring, MD, USA. 5. VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 6. University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA. 7. University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Abstract
AIMS: We compared the risk of mental health episodes requiring hospitalization (primary aim) or out-patient clinic visits (secondary aim) associated with varenicline versus the nicotine patch (NP) in an era prior to psychiatric boxed warnings. DESIGN: Retrospective cohort. SETTING: Department of Veterans Affairs (VA), USA. PARTICIPANTS: VA patients with or without psychiatric comorbidities and a new prescription for varenicline (15 255) were propensity score-matched (1 : 2) to new users of NP (123 054) between 1 May 2006 and 30 September 2007, resulting in 11 774 and 23 548 patients in the varenicline and NP groups, respectively. MEASUREMENTS: The primary outcomes were hospitalizations with a primary discharge diagnosis of a range of mental health disorders: depression, schizophrenia, bipolar disorder, suicide attempt, post-traumatic stress disorder, other psychosis and drug-induced mental disorders. Secondary outcomes were out-patient clinic visits with a primary diagnosis of the above list of mental health disorders. FINDINGS: Background characteristics of the treatment groups were similar after matching. There was no statistically significant difference in risk of hospitalization for any of the studied mental health disorders with varenicline compared with NP. Among secondary outcomes there was an increased risk of out-patient clinic visits for schizophrenia among patients who received varenicline [hazard ratio (HR) = 1.27; 95% confidence interval (CI) = 1.07, 1.51], this increase being evident only in those with a pre-existing mental health disorder. CONCLUSION: In US VA patients studied prior to the boxed warning being implemented, use of varenicline for smoking cessation was not associated with a detectable increase compared with nicotine patches in hospitalization for any mental health outcomes. There was an increased rate of out-patient attendances with a primary diagnosis of schizophrenia amounting to five per 100 person years of treatment. This increase was found only in patients with a pre-existing mental health disorder. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: We compared the risk of mental health episodes requiring hospitalization (primary aim) or out-patient clinic visits (secondary aim) associated with varenicline versus the nicotine patch (NP) in an era prior to psychiatric boxed warnings. DESIGN: Retrospective cohort. SETTING: Department of Veterans Affairs (VA), USA. PARTICIPANTS: VA patients with or without psychiatric comorbidities and a new prescription for varenicline (15 255) were propensity score-matched (1 : 2) to new users of NP (123 054) between 1 May 2006 and 30 September 2007, resulting in 11 774 and 23 548 patients in the varenicline and NP groups, respectively. MEASUREMENTS: The primary outcomes were hospitalizations with a primary discharge diagnosis of a range of mental health disorders: depression, schizophrenia, bipolar disorder, suicide attempt, post-traumatic stress disorder, other psychosis and drug-induced mental disorders. Secondary outcomes were out-patient clinic visits with a primary diagnosis of the above list of mental health disorders. FINDINGS: Background characteristics of the treatment groups were similar after matching. There was no statistically significant difference in risk of hospitalization for any of the studied mental health disorders with varenicline compared with NP. Among secondary outcomes there was an increased risk of out-patient clinic visits for schizophrenia among patients who received varenicline [hazard ratio (HR) = 1.27; 95% confidence interval (CI) = 1.07, 1.51], this increase being evident only in those with a pre-existing mental health disorder. CONCLUSION: In US VA patients studied prior to the boxed warning being implemented, use of varenicline for smoking cessation was not associated with a detectable increase compared with nicotine patches in hospitalization for any mental health outcomes. There was an increased rate of out-patient attendances with a primary diagnosis of schizophrenia amounting to five per 100 person years of treatment. This increase was found only in patients with a pre-existing mental health disorder. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
Adverse drug events; mental health disorder; nicotine replacement therapy; varenicline
Authors: Jennifer B McClure; Melissa L Anderson; Katharine Bradley; Lawrence C An; Sheryl L Catz Journal: JMIR Mhealth Uhealth Date: 2016-08-03 Impact factor: 4.773
Authors: Ravi J Desai; Meghan M Good; Alvaro San-Juan-Rodriguez; Andrew Henriksen; Francesca Cunningham; Inmaculada Hernandez; Chester B Good Journal: JAMA Netw Open Date: 2019-09-04
Authors: Catherine R Ayers; Jaimee L Heffner; Cristina Russ; David Lawrence; Thomas McRae; A Eden Evins; Robert M Anthenelli Journal: Depress Anxiety Date: 2019-12-18 Impact factor: 6.505